Skip to Content
Merck
All Photos(2)

Documents

53541

Supelco

Tulobuterol hydrochloride

VETRANAL®, analytical standard

Synonym(s):

2-tert-Butylamino-1-(2-chlorophenyl)ethanol hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C12H18ClNO · HCl
CAS Number:
56776-01-3
Molecular Weight:
264.19
MDL number:
MFCD00214398
UNSPSC Code:
41116107
PubChem Substance ID:
329757956
NACRES:
NA.24

grade

analytical standard

Quality Level

100

product line

VETRANAL®

Assay

≥98.0% (HPLC)

technique(s)

HPLC: suitable
gas chromatography (GC): suitable
solid phase extraction (SPE): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

storage temp.

2-8°C

SMILES string

Cl.CC(C)(C)NCC(O)c1ccccc1Cl

InChI

1S/C12H18ClNO.ClH/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13;/h4-7,11,14-15H,8H2,1-3H3;1H

InChI key

RSLNRVYIRDVHLY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Standard for Supelco MIP SPE cartridges. For more information request Supelco Literature T407075, T706019, T706030, T706020
Tulobuterol hydrochloride is a sympathomimetic amine, possessing bronchodilator activity.

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Tulobuterol hydrochloride may be used as a reference standard in determining the concentration of tulobuterol hydrochloride present in bovine liver homogenates and urine samples using gas chromatography coupled with tandem mass spectrometry (GC-MS-MS).

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK9925
BCCH6222
BCCD9390
BCCC1945
BCBX5290

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Determination of β2-receptor agonists in bovine urine and liver by gas chromatography?tandem mass spectrometry
Leyssens L, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications, 564(2), 515-527 (1991)
Gen Tamura et al.
Allergology international : official journal of the Japanese Society of Allergology, 61(2), 219-229 (2012-01-25)
Tulobuterol patch (HokunalinTM Tape), which contains a β(2)-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides
Masashi Kanehara et al.
Pulmonary pharmacology & therapeutics, 21(6), 874-878 (2008-11-06)
The airway inflammation of chronic obstructive pulmonary disease (COPD) demonstrates a poor response to the anti-inflammatory actions of corticosteroids. However, long-acting beta(2)-agonists and low-dose theophylline are reported to have a possible anti-inflammatory effect in COPD. The aim of this study
T Sakamoto et al.
Die Pharmazie, 64(6), 361-365 (2009-07-22)
Applicability of a Terahertz Pulsed Spectroscopy (TPS) and a Terahertz Pulsed Imaging (TPI) for detection of tulobuterol (TBR) crystals in transdermal patches was investigated. Because TBR has high permeability in dermis, crystalline TBR in patch matrices contributes to controlling the
Akinori Nakamura et al.
Chemical & pharmaceutical bulletin, 60(3), 300-305 (2012-03-03)
We proposed an in vitro/in vivo/in silico method for evaluating the clinical performance of matrix type transdermal therapeutic systems (TTSs). This method is based on the following four approaches: (1) drug release experiment, (2) in vitro penetration experiment using excised
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service